These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 3060240)

  • 1. Beta-lactamase inhibitors from laboratory to clinic.
    Bush K
    Clin Microbiol Rev; 1988 Jan; 1(1):109-23. PubMed ID: 3060240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of beta-lactamase inhibitors.
    Sutherland R
    J Reprod Med; 1990 Mar; 35(3 Suppl):307-12. PubMed ID: 2319512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of beta-lactamase-inhibitor combinations.
    Fuchs PC; Barry AL
    J Reprod Med; 1990 Mar; 35(3 Suppl):317-21. PubMed ID: 2319514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro].
    Blahová J; Hupková M; Krcméry V
    Cas Lek Cesk; 1995 Sep; 134(17):558-61. PubMed ID: 7553760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
    Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S
    Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
    Piddock LJ; Jin YF; Turner HL
    J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.
    Thomson KS; Weber DA; Sanders CC; Sanders WE
    Antimicrob Agents Chemother; 1990 Apr; 34(4):622-7. PubMed ID: 2344169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-lactamase inhibitors: another approach to overcoming antimicrobial resistance.
    Parker RH; Eggleston M
    Infect Control; 1987 Jan; 8(1):36-40. PubMed ID: 3028975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
    Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
    J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Stability of beta-lactamase inhibitors and beta-lactam antibiotics in parenteral formulations as well as in body fluids and tissue homogenates. Comparison of sulbactam, clavulanic acid, ampicillin and amoxicillin].
    Wildfeuer A; Räder K
    Arzneimittelforschung; 1991 Jan; 41(1):70-3. PubMed ID: 2049115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of beta-lactamase inhibitors.
    Jackson D
    Pharmacotherapy; 1991; 11(2 ( Pt 2)):37S-39S. PubMed ID: 2041830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of the in vitro activity of amoxycillin + clavulanic acid and ampicillin + sulbactam combinations against 50 Haemophilus influenzae strains producing beta lactamase].
    Moittie D; Simonet M; Veron M
    Pathol Biol (Paris); 1989 May; 37(5):390-3. PubMed ID: 2789362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.
    Payne DJ; Cramp R; Winstanley DJ; Knowles DJ
    Antimicrob Agents Chemother; 1994 Apr; 38(4):767-72. PubMed ID: 8031044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming enzymatic resistance in bacteria: impact on future therapy.
    Labia R; Barthélémy M; Péduzzi J; Morand A; Tiwari K; Kazmierczak A
    J Int Med Res; 1990; 18 Suppl 4():48D-57D. PubMed ID: 2282969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro effects of beta-lactams combined with beta-lactamase inhibitors against methicillin-resistant Staphylococcus aureus.
    Kobayashi S; Arai S; Hayashi S; Sakaguchi T
    Antimicrob Agents Chemother; 1989 Mar; 33(3):331-5. PubMed ID: 2786369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timentin and beta-lactamases.
    Labia R; Morand A; Péduzzi J
    J Antimicrob Chemother; 1986 May; 17 Suppl C():17-26. PubMed ID: 3487538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads.
    Jacobs MR; Aronoff SC; Johenning S; Yamabe S
    J Antimicrob Chemother; 1986 Aug; 18(2):177-84. PubMed ID: 3019984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in the potentiation of beta-lactam antibiotic activity by clavulanic acid and sulbactam against multiply antibiotic-resistant bacteria.
    Aldridge KE; Sanders CV; Marier RL
    J Antimicrob Chemother; 1986 Apr; 17(4):463-9. PubMed ID: 3011724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parenteral beta-lactamase inhibitor combinations for clinical use.
    Manzella JP
    Am Fam Physician; 1995 May; 51(7):1695-8. PubMed ID: 7754928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of sulbactam in combination with various beta-lactam antibiotics.
    Klastersky J; Van der Auwera P
    Diagn Microbiol Infect Dis; 1989; 12(4 Suppl):165S-169S. PubMed ID: 2591176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.